Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
出版年份 2019 全文链接
标题
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
作者
关键词
-
出版物
Frontiers in Oncology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-10-15
DOI
10.3389/fonc.2019.01015
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
- (2019) Huayu Yang et al. Frontiers in Oncology
- Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
- (2018) Lydia Giannopoulou et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors
- (2018) Wei Wei et al. MEDICINE
- Expression of multiple immune checkpoint molecules on T�cells in malignant ascites from epithelial ovarian carcinoma
- (2018) Yuichi Imai et al. Oncology Letters
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
- (2016) Jayanta Chatterjee et al. CLINICAL CANCER RESEARCH
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
- (2016) Steffen Filskov Sorensen et al. LUNG CANCER
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
- (2016) Issam Chebouti et al. Oncotarget
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
- (2015) Liang Wang et al. Oncotarget
- ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance
- (2014) J. D. Kuhlmann et al. CLINICAL CHEMISTRY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based Chemotherapy
- (2011) Bahriye Aktas et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started